相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The Genomic Heterogeneity of FIGO Grade 3 Endometrioid Carcinoma Impacts Diagnostic Accuracy and Reproducibility
Yaser R. Hussein et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY (2016)
Cancer Statistics, 2015
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2015)
Clinicopathological analysis of endometrial carcinomas harboring somatic POLE exonuclease domain mutations
Yaser R. Hussein et al.
MODERN PATHOLOGY (2015)
Synuclein γ protects Akt and mTOR and renders tumor resistance to Hsp90 disruption
W. Liang et al.
ONCOGENE (2015)
HER2 Immunohistochemistry Significantly Overestimates HER2 Amplification in Uterine Papillary Serous Carcinomas
Mark J. Mentrikoski et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2014)
Unconventional secretion of synuclein-γ promotes tumor cell invasion
Caiyun Liu et al.
FEBS JOURNAL (2014)
siRNA-Mediated Suppression of Synuclein γ Inhibits MDA-MB-231 Cell Migration and Proliferation by Downregulating the Phosphorylation of AKT and ERK
Jingsong He et al.
JOURNAL OF BREAST CANCER (2014)
Prognostic significance of overexpression of p53 in uterine endometrioid adenocarcinomas with an analysis of nuclear grade
Rie Urabe et al.
JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH (2014)
Synuclein γ Compromises Spindle Assembly Checkpoint and Renders Resistance to Antimicrotubule Drugs
Suyu Miao et al.
MOLECULAR CANCER THERAPEUTICS (2014)
Synuclein gamma protects HER2 and renders resistance to Hsp90 disruption
Yongfeng Shao et al.
MOLECULAR ONCOLOGY (2014)
Synuclein-gamma predicts poor clinical outcome in esophageal cancer patients
Didem Tastekin et al.
TUMOR BIOLOGY (2014)
Etiologic heterogeneity in endometrial cancer: Evidence from a Gynecologic Oncology Group trial
Louise A. Brinton et al.
GYNECOLOGIC ONCOLOGY (2013)
Expression of synuclein gamma indicates poor prognosis of triple-negative breast cancer
Kejin Wu et al.
MEDICAL ONCOLOGY (2013)
Neural protein gamma-synuclein interacting with androgen receptor promotes human prostate cancer progression
Junyi Chen et al.
BMC CANCER (2012)
Clinicopathological and prognostic impact of human epidermal growth factor receptor type 2 (HER2) and hormone receptor expression in uterine papillary serous carcinoma
Shinichi Togami et al.
CANCER SCIENCE (2012)
Synuclein-γ (SNCG) protein expression is associated with poor outcome in endometrial adenocarcinoma
Paulette Mhawech-Fauceglia et al.
GYNECOLOGIC ONCOLOGY (2012)
Pure Compared With Mixed Serous Endometrial Carcinoma Two Different Entities?
Thijs Roelofsen et al.
OBSTETRICS AND GYNECOLOGY (2012)
The Biphasic Role of NF-κB in Progression and Chemoresistance of Ovarian Cancer
Gong Yang et al.
CLINICAL CANCER RESEARCH (2011)
Uterine Papillary Serous, Clear Cell, and Poorly Differentiated Endometrioid Carcinomas A Comparative Study
Stefano Greggi et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2011)
Synuclein γ Stimulates Membrane-Initiated Estrogen Signaling by Chaperoning Estrogen Receptor (ER)-α36, a Variant of ER-α
Yuenian Eric Shi et al.
AMERICAN JOURNAL OF PATHOLOGY (2010)
Synuclein gamma predicts poor clinical outcome in colon cancer with normal levels of carcinoembryonic antigen
Caiyun Liu et al.
BMC CANCER (2010)
Minor Serous and Clear Cell Components Adversely Affect Prognosis in Mixed-Type Endometrial Carcinomas: A Clinicopathologic Study of 36 Stage-I Cases
M. Ruhul Quddus et al.
REPRODUCTIVE SCIENCES (2010)
HER2 gene amplification and EGFR expression in a large cohort of surgically staged patients with nonendometrioid (type II) endometrial cancer
G. E. Konecny et al.
BRITISH JOURNAL OF CANCER (2009)
Synuclein-γ (SNCG) may be a novel prognostic biomarker in uterine papillary serous carcinoma
Jacqueline Morgan et al.
GYNECOLOGIC ONCOLOGY (2009)
Applications of novel monoclonal antibodies specific for synuclein-γ in evaluating its levels in sera and cancer tissues from colorectal cancer patients
Caiyun Liu et al.
CANCER LETTERS (2008)
Serous carcinoma of the uterus-determination of HER-2/neu status using immunohistochemistry, chromogenic in situ hybridization, and quantitative polymerase chain reaction techniques: its significance and clinical correlation
P. Singh et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2008)
Synuclein-γ targeting peptide inhibitor that enhances sensitivity of breast cancer cells to antimicrotubule drugs
Vinay K. Singh et al.
CANCER RESEARCH (2007)
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer
Antonio C. Wolff et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Akt-mediated cisplatin resistance in ovarian cancer: Modulation of p53 action on caspase-dependent mitocliondrial death pathway
XK Yang et al.
CANCER RESEARCH (2006)
Synuclein gamma inhibits the mitotic checkpoint function and promotes chromosomal instability of breast cancer cells
S Inaba et al.
BREAST CANCER RESEARCH AND TREATMENT (2005)
Amplification of c-erbB2 oncogene - A maior prognostic indicator in uterine serous papillaty carcinoma
AD Santin et al.
CANCER (2005)
Racial differences in the overexpression of epidermal growth factor type II receptor (HER2/neu): A major prognostic indicator in uterine serous papillary cancer
AD Santin et al.
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY (2005)
AKT involvement in cisplatin chemoresistance of human uterine cancer cells
V Gagnon et al.
GYNECOLOGIC ONCOLOGY (2004)
Diagnostic potential in bladder cancer of a panel of tumor markers (calreticulin, γ-synuclein, and catechol-o-methyltransferase) identified by proteomic analysis
H Iwaki et al.
CANCER SCIENCE (2004)
Overexpression of synuclein-γ in pancreatic adenocarcinoma
ZK Li et al.
CANCER (2004)
γ synuclein, a novel heat-shock protein-associated chaperone, stimulates ligand-dependent estrogen receptor α signaling and mammary tumorigenesis
YF Jiang et al.
CANCER RESEARCH (2004)
Commenting on HER2/neu overexpression: has the Achilles' heel of uterine serous papillary carcinoma been exposed? (88:263-5) by Santin AD
BM Slomovitz et al.
GYNECOLOGIC ONCOLOGY (2004)
Breast cancer-specific gene 1 interacts with the mitotic checkpoint kinase BubR1
A Gupta et al.
ONCOGENE (2003)
Sustained activation of JNK/p38 MAPK pathways in response to cisplatin leads to Fas ligand induction and cell death in ovarian carcinoma cells
A Mansouri et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
γ-Synuclein promotes cancer cell survival and inhibits stress- and chemotherapy drug-induced apoptosis by modulating MAPK pathways
ZZ Pan et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
分享论文
